Please circulate and post Health Technology Assessment _HTA_ in

Document Sample
Please circulate and post Health Technology Assessment _HTA_ in Powered By Docstoc
					                                                                                             Please circulate and post

                                                                                                Light lunch will be provided
                                                                                                  on first come first serve

                                                School of Pharmacy
                                                Faculty of Medicine
                                        The Chinese University of Hong Kong

              “Health Technology Assessment (HTA) in Drug Evaluation Process
                            and its Latest Development in Asia”

                                                        Presented by
                        Prof. Kenneth KC Lee, J.P., BSc(Pharm), MPhil, PhD
                               Professor of Pharmacy and Head of Pharmacy,
                                          Sciences                          campus
           School of Medicine and Health Sciences, Monash University Sunway campus, Malaysia

Date:            Jan 27, 2011 (Thu) at 12:30pm
Venue:           Rm 601, Choh-Ming Li Basic Medical Sciences Building, Chinese University of Hong Kong

Health technology assessment (HTA) is a form of policy research that examines short- and long-term consequences of the
application of a health care technology. Health care technology within the concept of HTA includes drugs, biologics, devices,
 pp                                  gy                      gy                 p                     g,       g ,          ,
procedures, support systems, health programs etc.

The goal of HTA is to provide policy makers with information on policy alternatives. For any given technology, properties and
impacts assessed may include technical properties, evidence of safety, efficacy, real-world effectiveness, cost, and cost-
effectiveness as well as estimated social, legal, ethical, and political impacts. HTA is commonly performed to support decision-
making processes to advise the appropriate use and purchase of technology, inform payers regarding health plan coverage and
payment etc. Today, many governments around the world including Asia have created internal agencies authorized to include a
broad HTA service. There are also private HTA agencies established with similar functions. The governments look to these
agencies to guide them in a diversity of policy decisions. Their reports are viewed as useful guidance for technology adoption
and reimbursement decision making.

This 45min presentation aims to introduce to the audience the fundamental concepts of HTA in the context of drug evaluation, its
applications in a health care system, the process of performing an HTA, and the usual methods to interpret the results. The
audience will also be updated on the latest situation in Asia with regards to HTA.

Biographical Sketch
Kenneth Lee is Professor of Pharmacy and Head of Pharmacy, School of Medicine and Health Sciences, Monash University
Sunway campus, Malaysia. He was formerly Professor and Associate Director of External Affairs of the Chinese University of
HK School of Pharmacy of which he was a founding member. His concurrent academic appointments include Visiting Professor
of the University of London School of Pharmacy, Adjunct Professor of the CUHK School of Pharmacy, and Honorary Professor
of the School of Public Health, the University of Hong Kong. He was appointed by the Government of HK as a Justice of Peace
in 2003 for his outstanding community services.
Kenneth Lee obtained his undergraduate degree in pharmacy from the University of Washington in Seattle, USA, and his
subsequent higher qualifications from the Chinese University of Hong Kong.

Kenneth Lee is one of the pioneers in health economics research in Hong Kong, and was the founding president of the HK
Chapter of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in 1999. He also played an
instrumental role in the establishment of the ISPOR Asia Consortium and was the Chair of 2006-2008. He has been recently
selected as Chair of the Publication Committee of the Consortium.

He has been Editor-in-chief of the Journal of Medical Economics since 2007. He is also a reviewer and sits on the editorial board
of a number of regional and international journals.

Shared By: